SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-047759
Filing Date
2023-02-24
Accepted
2023-02-24 09:27:04
Documents
18
Period of Report
2023-02-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d454389d8k.htm   iXBRL 8-K 37816
2 EX-1.1 d454389dex11.htm EX-1.1 179028
3 EX-4.1 d454389dex41.htm EX-4.1 73268
4 EX-5.1 d454389dex51.htm EX-5.1 15180
5 EX-99.1 d454389dex991.htm EX-99.1 8719
9 GRAPHIC g454389g0223103903629.jpg GRAPHIC 1649
10 GRAPHIC g454389g0223122707068.jpg GRAPHIC 6662
  Complete submission text file 0001193125-23-047759.txt   528243

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA apls-20230222.xsd EX-101.SCH 2851
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20230222_lab.xml EX-101.LAB 17236
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20230222_pre.xml EX-101.PRE 10813
12 EXTRACTED XBRL INSTANCE DOCUMENT d454389d8k_htm.xml XML 3202
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 23662765
SIC: 2834 Pharmaceutical Preparations